Decreased microRNA‑768‑3p expression indicates a poor prognosis in patients with breast cancer and promotes breast cancer cell viability, migration and invasion
- Yanhua Zhou
- Ying Wang
- Lili Wang
- Jing Zhang
- Xin Liu
Affiliations: Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Quality Control Division, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Operating Room, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China
- Published online on: June 2, 2021 https://doi.org/10.3892/ol.2021.12840
Copyright: © Zhou
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Breast cancer is the most common malignancy in women and microRNA‑768‑3p (miR‑768‑3p) is abnormally expressed in hepatocellular carcinoma, non‑small cell lung carcinomas and melanoma. The aim of the present study was to evaluate the prognostic value and biological function of miR‑768‑3p in breast cancer. The expression of miR‑768‑3p in tumor tissues and adjacent tissues of 116 patients with breast cancer obtained by surgery and normal breast cell lines MCF‑10A and breast cancer cell lines (MCF‑7, MDA‑MB‑231, T‑47D and SK‑BR‑3) were detected by reverse transcription‑quantitative PCR. The association between miR‑768‑3p expression and the clinicopathological characteristics of patients was analyzed using the χ2 test. In addition, the Kaplan‑Meier method was used for survival analysis. A Cox regression model was used to examine the effect of miR‑768‑3p on the prognosis of patients with breast cancer. Hemocytometer cell counting and Transwell assays were used to detect the effects of miR‑768‑3p on the characteristics of breast cancer cells. The target genes of miR‑768‑3p in breast cancer were identified by bioinformatics software and detected by luciferase reporter assay. Compared with normal tissues and normal breast cancer cells, miR‑768‑3p was significantly decreased in breast cancer tissues and cancer cells (P<0.001). The reduction in miR‑768‑3p was significantly associated with lymph node metastasis (P=0.040), Tumor Node Metastasis stage (P=0.035), and cancer subtype (P=0.008). In addition, patients with low miR‑768‑3p expression had a shorter overall survival time (log‑rank P=0.022) compared with those with high expression and miR‑768‑3p may be a potential prognostic marker (hazard ratio=4.637; 95% confidence interval=1.296‑16.597; P=0.018). When transfected with miR‑768‑3p inhibitor, cell viability, migration and invasion were significantly promoted compared with the control group (P<0.05). In addition, eukaryotic translation initiation factor 4E (eIF4E) was the target gene of miR‑768‑3p in breast cancer. All experiments confirmed that miR‑768‑3p, a tumor suppressor, inhibited the viability, migration and invasion of breast cancer cells through eIF4E. miR‑768‑3p may be a potential prognostic marker of breast cancer and may participate in the progression of breast cancer.